Clinical trials

#Clinical trials #Cytel

Cytel appoints new CMO to drive product development  

Software company Cytel has appointed a new chief medical officer (CMO) to help drive growth in the field of advanced analytics capabilities.   Cytel has appointed Dr Albert Kim as its CMO to help it advance product development throughout the company. Dr Kim has previously held roles at… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and Gene Therapy Catapult #Clinical trials

UK recognised as ATMP leader in clinical trials, report states

The UK has been highlighted as a leader in clinical trials for Advanced Therapy Medicinal Products (ATMPs), after a report published by the Cell and Gene Therapy Catapult (CGT Catapult) displayed the sector’s continued growth in the UK. The report CGT Catapult’s 2021 Advanced Therapy Medicinal Product (ATMP) report… Read More

#News

#Clinical trials #Diabetes

Atrogi gets go-ahead to begin Phase I study of type 2 diabetes therapy

Early-stage biopharma company Atrogi has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany to initiate a Phase I study for its drug candidate targeting type 2 diabetes. The approval means that Atrogi will be able to launch a Phase I study for its… Read More

#News

#Asthma #AstraZeneca #Clinical trials

New data reinforce efficacy of asthma drug 

Results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated reductions in the annualised asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 According to the company, these findings support… Read More

#News

#Clinical trials #Events #Life sciences #Oncology #Rare disease

BioTrinity 2022: Catalysing growth in the life sciences industry 

BioTrinity 2022 will take place April 26-27, 2022 at 155 Bishopsgate in London, UK.   The BioTrinity conference aims to catalyse growth and supports in-person engagement across the life sciences industry. The event will be attended by early-stage and emerging life sciences R&D companies, investors, large pharma,… Read More

#News

#Clinical trials #CRO #Whitepaper

Whitepaper: How to reduce your clinical study budget by 55%

Learn how to reduce your clinical study budget by 45-55% in Central and Eastern Europe by downloading this Whitepaper by Research Professionals CRO. This whitepaper identifies the most significant cost elements of a typical clinical study budget and breaks it… Read More

#News

#Clinical trials #Comment #Pharmaceuticals

Do end-to-end CDMOs hold the secret to success in cell and gene therapy?

The cell and gene therapy (CGT) industry is booming, say Sergio Lainez Vicente (Senior Manager of Business Operations in the Cell & Gene Therapy / Large Molecule area) and Jaleel Shujath (Vice President of Marketing and Content), at Absorption Systems, a Pharmaron company. Around 1200 potential cell and gene therapies… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#AI / data analytics / healthtech / informatics #Biotechnology #Clinical trials #Comment #Data science #Decentralised clinical trials #Digital

Predictions and perspectives on the future of DCTs 

"The message was clear from industry leaders this year whether on social media or conferences: today’s clinical trials need decentralised solutions", says Temitope Keyes, Executive Director Business Development at encapsia, commenting on the decentralised clinical trial (DCT) event horizon.  Clinical trials are now more complex than ever, and sites and… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Clinical trials #Collaboration

New organisation promises smart clinical trials for better health 

Protas, a non-profit organisation which was launched on January 24, will design and deliver large, inclusive, randomised clinical trials, working in collaboration with industry partners, medical charities, patient groups, academic researchers, and frontline clinical teams. Sanofi is its first strategic partner.  Outlook  By combining randomised trial design with effective technology and a collaborative… Read More

#News

Human liver
#Clinical trials #Liver disease #Oncology #Therapeutics #Tumours

First patient dosed in advanced liver cancer clinical trial 

MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).  What is OUTREACH-2?  OUTREACH-2 is a multi-centre,… Read More

#News #Trending News

#Clinical trials #Healthcare #Public health #Training

Psychotherapists begin training for treatment resistant depression trials 

Beckley Psytech has announced that the first cohort of psychotherapists have begun training in advance of the expected Phase II clinical trial examining 5-MeO-DMT-assisted psychotherapy in treatment resistant depression (TRD).   The training  The training is being conducted in collaboration with Fluence, an educational platform that provides professional… Read More

#News

#Biotechnology #Clinical trials #Imaging

Industry predictions for clinical trials 

Medidata reflects on how clinical trials have evolved over the past year, as well as emerging patterns and drivers of change for the coming year. Paul O’Donohoe and Fiona Maini from Medidata explain.  1. The future of clinical trials is decentralised  Decentralised clinical trials, described as the ‘new normal’ in clinical research, harness remote technologies to… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Biotechnology #Clinical trials #Drug development #Tumours

Avacta takes step to increase the tolerability of chemotherapies  

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.  The technology  Avacta’s chemistry is used to modify chemotherapy drugs to render them inactive… Read More

#News

Human eye
#Clinical trials #Comment #Covid-19 #Eye health

Innovative delivery: sustained ophthalmic steroids in diabetic macular edema 

Listen to this article on the DDW Podcast: Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies, UCL Institute of Ophthalmology, and Consultant Ophthalmologist, Moorfields Eye Hospital, UK discusses unmet needs in DME therapeutics and how they could be addressed by sustained release ophthalmic steroids administered with novel suprachoroidal drug delivery methods.  Diabetic eye… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Antibodies #Autoimmune disease #Clinical trials #Therapeutics

eBook: Antibody production

In immunoassays-based research, immunodiagnostics, as well as immunotherapy, one of the highly critical aspect of antibodies is their reproducible performance. Antibody reproducibility is driven by their specificity and several other factors ranging from antibody design to target validation. This NEW eBook Antibody Production gives you an overview of the… Read More

#News

#Cancer research #Clinical trials #Drug development #Molecular research #Oncology #Personalised medicine

Exclusive: The personalised medicine paradigm

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More

#Editor's Choice #Exclusive Content #News